A study by the University of Barcelona reveals that the combination of palbociclib and telaglenastat, two drugs with complementary actions, could help improve the clinical treatment of this type of ca...
Read more
The global phase II/III randomized RELATIVITY-047 study evaluated the immunotherapy combination of nivolumab and relatlimab compared to nivolumab monotherapy for patients with previously untreated met...
Read more
La investigación, liderada por equipos de IBIMA, el Hospital Regional Universitario de Málaga, la Universidad de Málaga y el CIBERDEM, revela beneficios en el bienestar, la composición corporal y ...
Read more
Palobiofarma S.L., una empresa biofarmacéutica dedicada al descubrimiento y desarrollo de fármacos innovadores para enfermedades huérfanas, ha anunciado hoy el logro de varios hitos importantes en ...
Read more
SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative light-signaling cascade in malfunctioning cone photoreceptors
Read more
Across all reviews, tirzepatide, semaglutide, and liraglutide produced significant weight loss compared with placebo after one or two years, and these effects are likely to continue as long as treatme...
Read more
Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD
Read more
At Abyntek, they work with antibodies that not only guarantee the highest quality and are backed by hundreds of scientific references, but also offer a key advantage for research: you can use them acr...
Read more
A research team has developed pioneering technology that enables human kidney organoids to be produced on a scalable basis. These organoids can then be combined with pig kidneys outside the body and t...
Read more
Through a review of their structural characteristics, cargo capacity, behavior in clinical studies, and immune response, the article offers a practical overview for researchers looking to optimize the...
Read more
Preliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rate
Read more
Alzheimer’s disease (AD) is one of the most significant and pressing challenges in modern healthcare. Affecting more than 50 million people worldwide1, AD places an immense and growing social and ec...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
